-
Mashup Score: 4Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion - 8 hour(s) ago
PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO’s membership following publication or presentation of potentially practice-changing data from major studies. This provisional clinical opinion addresses the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors. CLINICAL CONTEXT An increasing number of therapies are approved to treat cancers harboring specific genomic biomarkers. However, there is a lack of clarity as to when tumor genomic sequencing should be ordered, what type of assays should be performed, and how to interpret the results for treatment selection. PROVISIONAL CLINICAL OPINION Patients with metastatic or advanced cancer should undergo genomic sequencing in a certified laboratory if the presence of one or more specific genomic alterations has regulatory approval as biomarkers to guide the use of or exclusion from certain treatments for their disease. Multigene panel–based assays should be used i
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
The data and technology company is partnering with BillionToOne on diagnostic solutions in oncology.
Source: www.healthcarefinancenews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 0Coordinating an Oncology Precision Medicine Clinic Within an Integrated Health System: Lessons Learned in Year One - 15 day(s) ago
Precision medicine is a term describing strategies to promote health and prevent and treat disease based on an individual’s genetic, molecular, and lifestyle characteristics. Oncology precision medicine (OPM) is a cancer treatment approach targeting cancer-specific genetic and molecular alterations. Implementation of an OPM clinical program optimally involves the support and collaboration of multiple departments, including administration, medical oncology, pathology, interventional radiology, genetics, research, and informatics. In this review, we briefly introduce the published evidence regarding OPM’s potential effect on patient outcomes and discuss what we have learned over the first year of operating an OPM program within an integrated health care system (Aurora Health Care, Milwaukee, WI) comprised of multiple hospitals and clinics. We also report our experience implementing a specific OPM software platform used to embed molecular panel data into patients’ electronic medical recor
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet-
Coordinating an Oncology #PrecisionMedicine Clinic w/in an Integrated Health System: Lessons Learned in Year 1 [1/28/19] @mtmdphd Godden, Wham @antonyruggeri @mullane_michael Wilson @shamsvirani Weissman, Ramczyk, Vanderwall @JimW9200 @Aurora_Cancer @JPCRR https://t.co/bxgjOfLhwk https://t.co/yd53qWlVFb
-
-
Mashup Score: 6
PURPOSE With the advent of precision medicine, molecular tumor boards (MTBs) were established to interpret genomic results and guide decision making for targeted therapy in oncology patients. There are currently no universal guidelines for how MTBs should operate and thus variance can be seen depending on which MTB is reviewing the case. This study assesses the concordance of MTB recommendations when a participant case is reviewed by two different MTBs, establishes potential reasons for discordance, and advocates for the establishment of standard MTB operating guidelines. PATIENTS AND METHODS Participants with advanced cancer, who had exhausted all standard treatment options were screened for the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cases were submitted for MTB review if the treatment proposal was outside the protocol genomic matching rules, or if multiple treatment options were identified. Of the 306 cases submitted for review by the TAPUR MTB from 2016 to
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer - 21 day(s) ago
PURPOSE This review summarizes the published evidence on the clinical impact of using next-generation sequencing (NGS) tests to guide management of patients with cancer in the United States. METHODS We performed a comprehensive literature review to identify recent English language publications that presented progression-free survival (PFS) and overall survival (OS) of patients with advanced cancer receiving NGS testing. RESULTS Among 6,475 publications identified, 31 evaluated PFS and OS among subgroups of patients who received NGS-informed cancer management. PFS and OS were significantly longer among patients who were matched to targeted treatment in 11 and 16 publications across tumor types, respectively. CONCLUSION Our review indicates that NGS-informed treatment can have an impact on survival across tumor types.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Coordinating an Oncology Precision Medicine Clinic Within an Integrated Health System: Lessons Learned in Year One - 21 day(s) ago
Precision medicine is a term describing strategies to promote health and prevent and treat disease based on an individual’s genetic, molecular, and lifestyle characteristics. Oncology precision medicine (OPM) is a cancer treatment approach targeting cancer-specific genetic and molecular alterations. Implementation of an OPM clinical program optimally involves the support and collaboration of multiple departments, including administration, medical oncology, pathology, interventional radiology, genetics, research, and informatics. In this review, we briefly introduce the published evidence regarding OPM’s potential effect on patient outcomes and discuss what we have learned over the first year of operating an OPM program within an integrated health care system (Aurora Health Care, Milwaukee, WI) comprised of multiple hospitals and clinics. We also report our experience implementing a specific OPM software platform used to embed molecular panel data into patients’ electronic medical recor
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet-
Coordinating an Oncology #PrecisionMedicine Clinic w/in an Integrated Health System: Lessons Learned in Year 1 [1/28/19] @mtmdphd Godden, Wham @antonyruggeri @mullane_michael Wilson @shamsvirani Weissman, Ramczyk, Vanderwall @JimW9200 @Aurora_Cancer @JPCRR https://t.co/bxgjOfLhwk https://t.co/yd53qWlVFb
-
-
Mashup Score: 1Role of Community-Based Genomics Programs - 21 day(s) ago
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or po.ascopubs.org/site/ifc. Speakers’ Bureau: Syapse, Novartis, Precision Medicine Travel, Accommodations,
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11NCI Precision Oncology | LinkedIn - 26 day(s) ago
NCI Precision Oncology | 186 followers on LinkedIn. NCI Privacy Policy: https://www.cancer.gov/policies/privacy-security
Source: www.linkedin.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Lurie Cancer Center OncoSET Symposium - 1 month(s) ago
On Friday, April 26th, the OncoSET Symposium will provide healthcare professionals with state of the art information related to new advances in precision medicine looking beyond mutations in cancer treatment and care. The program will focus on improving the detection of fusions and their therapeutic vulnerabilities, enhancing future incorporation of multiomics assays into management decisions and discussing established and future molecular imaging targets. Participants will learn strategies for translating advances in precision medicine to their clinical practice.
Source: www.cancer.northwestern.eduCategories: General Medicine News, Onc News and JournalsTweet-
Join us April 26 for the Lurie Cancer Center OncoSET Symposium — Precision Oncology: Beyond Mutations. View the agenda and register now to learn about strategies for translating advances in #precisionmedicine into practice. https://t.co/dn8dQ2wPSp @NorthwesternMed @NUFeinbergMed https://t.co/pX2YqtJMBk
-
-
Mashup Score: 14Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer - 2 month(s) ago
npj Precision Oncology – Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: @ASCO Provisional Clinical Opinion [Feb 17, 2022] @CDebyaniPhD et al. @JCO_ASCO https://t.co/hfHUBS3Unx #PrecisionMedicine https://t.co/wRkLVTgFZw